These stocks are the most oversold in the selloff and could be due for a bounce

Following a broad market downturn driven by concerns over AI stock valuations and weak consumer sentiment, several S&P 500 companies are exhibiting extreme Relative Strength Index (RSI) readings. Fintech firm Fiserv is highlighted as the most oversold with an RSI of 14, having plummeted 44% after slashing guidance due to Argentina's economic woes, though analysts still project substantial upside. DoorDash is also significantly oversold (RSI 23.8) after missing Q3 profit estimates and announcing considerable future spending on new initiatives. Conversely, Eli Lilly is identified as highly overbought (RSI 72.4) after strong Q3 results and raised guidance, propelled by robust demand for its weight-loss drugs and potential expanded coverage, despite analysts forecasting limited additional gains.

Analysis

The broader market experienced a challenging week, with all major U.S. indexes declining amidst concerns over AI stock valuations, weak consumer sentiment, and rising layoff announcements. This environment has led to extreme technical readings, with several S&P 500 stocks exhibiting oversold or overbought conditions based on their 14-day Relative Strength Index (RSI).

Fintech firm Fiserv (FI) is the most oversold with an RSI of approximately 14, following a 44% single-day decline and a 69% year-to-date drop. This downturn was triggered by a significant cut to full-year guidance and executive changes, largely attributed to Argentina's economic deterioration. Despite multiple analyst downgrades, the average analyst price target of $106.02 still implies a substantial 66.6% potential upside. DoorDash (DASH) is also significantly oversold with an RSI of 23.8, having fallen nearly 19% week-to-date after missing Q3 profit forecasts and announcing substantial future investments.

Conversely, Eli Lilly (LLY) is highly overbought with an RSI of 72.4, driven by a strong 6.4% weekly gain and a 19% year-to-date increase. The pharmaceutical giant reported robust Q3 earnings, beating top and bottom lines, and raised its full-year outlook, primarily due to strong demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro. While investor optimism is high, consensus price targets suggest limited further upside of around 3%. McKesson (MCK) also appears overbought, rising 5% this week and 49.5% this year, after raising its fiscal year 2026 profit forecast.

Key Decisions for Investors

• Investors should evaluate the potential for a technical bounce in deeply oversold stocks like Fiserv and DoorDash, while carefully assessing the underlying fundamental issues that led to their declines.
• Consider Eli Lilly's long-term growth prospects, particularly its weight-loss drug franchise, despite its current overbought technical status and analyst consensus for limited near-term upside.
• Monitor broader macroeconomic indicators, such as consumer sentiment and layoff data, as these factors are contributing to market volatility and could impact investment strategies.